The U.S. Supreme Court will decide whether shareholders can sue Merck & Co. over whether the drug maker provided adequate information about the risks of its former blockbuster painkiller Vioxx before the drug was pulled from the market.
The high court agreed to review Merck's challenge to a federal appeals court's reinstatement of a class-action securities lawsuit.
